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CC BY-NC-ND license (http://creativeAbstract The aim of this study was to investigate the effects of tadalafil (TDF) and pentox-
ifylline (PTX) on hepatic apoptosis and the expressions of endothelial and inducible nitric oxide
synthases (eNOS and iNOS) after liver ischemia/reperfusion (IR). Forty Wistar albino rats were
randomly divided into five groups (nZ 8) as follows: sham group; IR group with ischemia/re-
perfusion alone; low-dose and high-dose TDF groups received 2.5 mg/kg and 10 mg/kg TDF,
respectively; and PTX group received 40 mg/kg PTX. Blood was collected for the analysis of
serum alanine aminotransferase, aspartate aminotransferase, g-glutamyl transferase, uric
acid, malondialdehyde (MDA), and total antioxidant capacity (TAC). MDA and TAC also were
measured in liver tissue. Histopathological examination was performed to assess the severity
of hepatic injury. Apoptosis was evaluated using the apoptosis protease-activating factor 1
(APAF-1) antibody; the expressions of eNOS and iNOS were also assessed by immunohistochem-
istry in all groups. Serum alanine aminotransferase, aspartate aminotransferase, g-glutamyl
transferase, uric acid, MDA, and TAC, tissue MDA and TAC levels, hepatic injury, and score
for extent and for intensity of eNOS, iNOS, and apoptosis protease-activating factor 1 were
significantly different in TDF and PTX groups compared to the IR group. High dose-TDF and
PTX have the best protective effect on IR-induced liver tissue damage. This study showed thateclare no conflicts of interest.
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340 S. Bektas et al.TDF and PTX supplementation may be helpful in preventing free oxygen radical damage, lipid
peroxidation, hepatocyte necrosis, and apoptosis in liver IR injury and minimizing liver
damage.
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Ischemia/reperfusion (IR) injury results from prolonged
ischemic damage followed by restoration of blood
perfusion. IR injury is a serious complication of liver
surgery, transplantation, and various forms of circulatory
shock. Liver IR injury is a complex cascade of events
mediated by numerous inflammatory cells and molecular
mediators, resulting in hepatocyte death and systemic
inflammatory response. The degree of inflammatory
response and organ dysfunction is dependent on the
duration of liver ischemia and underlying liver disease
[1e3]. A large number of pharmacological agents have
been shown to confer protection against IR injury in the
liver. These agents include antioxidants, ozone, adeno-
sine agonists, nitric oxide donors, sildenafil, and varde-
nafil [3e5]. Nevertheless, only a few drugs are currently
introduced into clinical practice.
Tadalafil (TDF) is a potent and selective inhibitor of
phosphodiesterase type-5 (PDE5), which was originally
studied as a potential antianginal agent, but became
popular for its use in treatment of erectile dysfunction
and pulmonary arterial hypertension. Hepatic vascular
resistance is regulated by contraction or relaxation of
smooth muscle cells in terminal arterioles. By contrast,
perisinusoidal stellate cells regulate sinusoidal tonus
depending on concentration of nitric oxide (NO) synthe-
sized by sinusoidal endothelial cells. TDF is a specific in-
hibitor of the NO/cyclic guanosine monophosphate (cGMP)
pathway in vascular smooth muscle and platelets, which
results in vasodilation of peripheral arteries and veins and
inhibition of platelet aggregation respectively. NO gen-
erates cGMP, which induces cellular response such as
vasodilation. cGMP is inactivated to GMP by phosphodi-
esterases. Inhibition of PDE augments and prolongs the
cellular responses of vasodilation induced by NO and its
products. [6,7]. NO is synthesized by one of three NO
synthase (NOS) isoforms. The expression of neuronal NOS
is mostly limited to neural tissue. Inducible NOS (iNOS) is
not expressed under normal circumstances but is upre-
gulated during inflammatory conditions in hepatocytes,
endothelial cells, biliary cells, Kupffer cells, neutrophils,
and T lymphocytes. Endothelial NOS (eNOS) is constitu-
tively expressed in many cell types, including liver endo-
thelial cells and hepatocytes. Several studies have
revealed the protective effect of TDF on renal, myocar-
dial and testicular IR injury [8e10].
Pentoxifylline (PTX) is a nonspecific type-4 PDE inhibi-
tor that displays vasodilatory effects on peripheral blood
vessels, particularly in the liver [11]. Some studies have
indicated that PTX treatment restores depressed cardiacoutput and improves hepatic perfusion and intestinal
blood flow after hemorrhage and resuscitation [3,12,13].
PTX has been reported to suppress the production of
tumor necrosis factor-a, interleukin (IL)-1, IL-6, and IL-12
and to reduce oxidative stress and inflammatory indices
[14,15]. Although TDF and PTX have demonstrated bene-
ficial effects, the mechanisms by which these drugs exert
protective effects are not fully understood in liver IR
injury.
Several mechanisms exist to inhibit IR injury and many
drugs have also shown protective effects. The protection
mechanisms against IR-induced injury are multifactorial. A
number of mechanisms have been proposed, including the
elimination of free radicals, inhibition of free radical pro-
duction, neutrophilic inhibition, and reduction of lipid
peroxidation [6,7,12e14]. Although the basic pathological
mechanism underlying hepatic injury is not completely
understood, it has been shown that reactive oxygen spe-
cies, formed during IR and apoptosis play an important role
in this process. This is the first experimental study in which
the effect of two different PDE inhibitors on liver IR injury
was investigated. The purpose of this study was to establish
the impact of TDF and PTX on hepatic apoptosis and the
expressions of eNOS and iNOS in IR-induced liver tissue
damage.Methods
The experimental protocols were conducted with the
approval of the Animal Research Committee at Bulent
Ecevit University, Kozlu, Zonguldak. All animals were
maintained in accordance with the recommendations of the
National Institutes of Health Guidelines for the Care and
Use of Laboratory Animals.
Animal model
Forty female Wistar rats weighing 250e300 g were housed
individually in cages, and were allowed free access to
standard rat chow and water before the experiments. The
animal rooms were windowless with temperature (22 2C)
and lighting controls. The animals were fasted overnight
before the experiments but were given free access to
water. They were anesthetized by 100 mg/kg ketamine
intraperitoneally. All surgical interventions were performed
under sterile conditions by the same surgical team at the
same period and environment. After midline laparotomy,
the left and median liver lobes were rendered ischemic
with a microvascular clamp. The successful occlusion of the
hepatic artery and portal triad branch in question was
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hepatic ischemia lasted 90 minutes and was followed by 2
hours of reperfusion. At the end of reperfusion period, the
animals were sacrificed by exsanguination through cardiac
puncture and blood collection. The blood was immediately
centrifuged, and the plasma supernatant was stored at
80C until it was assayed for biochemical studies. The left
and median liver lobes were harvested at the end of each
procedure for histopathology, immunohistochemistry, and
biochemical analysis.Experimental groups
Sham group (nZ 8): Animals subjected to anesthesia, only
laparotomy and mobilization of liver (without induction of
hepatic ischemia); IR group (nZ 8): Animals subjected to IR
procedures alone; Low-dose TDF (nZ 8) and high-dose TDF
(nZ 8) groups: Animals received 2.5 mg/kg and 10 mg/kg
TDF by gastric gavage, respectively and underwent IR pro-
cedures after 45 minutes; PTX group (nZ 8): Animals
received 40 mg/kg PTX by gastric gavage and underwent IR
procedures after 45 minutes.Biochemical analysis
Blood
Blood was collected into tubes at the time of death. Blood
samples were centrifuged at 1000 g for 10 minutes at 4C to
remove plasma. Aliquots of the samples were transferred
into polyethylene tubes to be used in the assay of
biochemical parameters and were stored at 80C until
analysis.
Tissue
All tissues were washed twice with cold saline solution,
placed into glass bottles, labeled, and stored in a deep
freezer (80C) until processing. Liver tissues were ho-
mogenized in 10 volumes of 150mM ice-cold KCl using a
glass Teflon Homogenizer (Ultra Turrax IKA T18 Basic; IKA,
Wilmington, NC, USA) after cutting the tissues into small
pieces with scissors (for 2 minutes at 5000 rpm). The ho-
mogenate was then centrifuged at 5000 g for 15 minutes.
The supernatant was used for analysis.
Assay of biochemical parameters
Malondialdehyde (MDA) was assayed with a commercial kit
(Immundiagnostik AG, Bensheim, Germany) that is based
on the high-performance liquid chromatography method
using an Agilent 1200 HPLC system (Agilent, San Jose, CA,
USA). Antioxidant capacity was analyzed using a TAS Kit
(Randox, Crumlin, Antrim, UK) according to the manu-
facturer’s instructions. Measurements were performed
using a Shimadzu UV-1601 (Shimadzu, Kyoto, Japan)
spectrophotometer. Alanine aminotransferase (ALT),
aspartate aminotransferase (AST), uric acid (UA), and g-
glutamyl transferase (GGT) levels were measured with
commercially available kits on an Advia 2400 automated
analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY,
USA). Protein concentrations of the supernatants were
determined by the method described by Lowry et al. [16].Histopathological evaluation
Liver tissues were fixed in 10% buffered formaldehyde and
prepared for routine paraffin embedding. Tissue sections
(5 mm) were then stained with hematoxylin and eosin and
examined under a light microscope (Olympus- BH-2,
Wendenstrasse, Hamburg, Germany) by an experienced
pathologist, who was unaware of the treatment conditions.
A semiquantitative histopathological evaluation of the
severity of the hepatic injury was graded on a scale as
follows: Grade 0, minimal or no evidence of injury; Grade 1,
mild injury consisting of cytoplasmic vacuolation and focal
nuclear pyknosis; Grade 2, moderate to severe injury with
extensive nuclear pyknosis, cytoplasmic hypereosinophilia,
and loss of intercellular borders; and Grade 3, severe ne-
crosis with disintegration of hepatic cords, hemorrhage,
and neutrophil infiltration [5].
Immunohistochemical staining
Sections (5 mm) were deparaffinized in xylene, and then
dehydrated. 3% hydrogen peroxide was used for blocking
endogenous peroxidase activity. Antigen retrieval was car-
ried out by incubation in citrate buffer (pH 6.0) for 10 mi-
nutes in a pressure cooker. The sections were exposed to the
primary antibodies to eNOS [rabbit polyclonal anti-human
immunoglobulin (IgG), clone: C-20, 1:100 dilution; Santa
Cruz Biotechnology, Inc., Heidelberg, Germany], iNOS (rab-
bit polyclonal anti-human IgG, clone: N-20, 1:100 dilution;
Santa Cruz Biotechnology), and APAF-1 (mouse monoclonal
anti-human IgG, clone: 2E10, 1:100 dilution; Santa Cruz
Biotechnology) for 60 minutes at room temperature. The
standard streptavidin-biotin-peroxidase complex method
was used for primary antibodies and by employing dia-
minobenzidine as the chromogen. Intense brown staining of
the cytoplasm was considered as a positive reaction for
eNOS, iNOS, and APAF-1. Samples of colorectal carcinoma
and placenta were used as a positive control for APAF-1 and
eNOSeiNOS expressions, respectively. Negative controls
were obtained by omitting the primary antibody.
Evaluation of immunohistochemical staining
We calculated the immunohistochemical score for extent
and for intensity of eNOS, iNOS, and APAF-1 for each liver
tissue according to the previously published methods [10].
The intensity of the immune expression was categorized
into four groups: no staining (0), weak (þ1), moderate
(þ2), and strong (þ3). The extent of epithelial cells with
positive cytoplasmic staining was estimated and classified
on a four-point scale: no stainingZ 0; 1Z 1e9%;
2Z 10e49%; and 3Z 50e100%.
Statistical analysis
Statistical analysis was performed with SPSS version 18.0
software (SPSS Inc., Chicago, IL, USA). All values were
expressed as the mean standard error of mean. Differ-
ences between the groups were evaluated by one-way
analysis of variance test with posthoc multiple compari-
sons, ManneWhitney U test, and KruskaleWallis test.
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all tests.Results
Biochemical results
Serum ALT, AST, and GGT levels, which were used as indices
of hepatic injury, showed a significant increase (p< 0.05) in
the IR group, while high-dose TDF and PTX administration
prevented this effect (p< 0.05); there was no significant
difference between low-dose TDF and IR groups (p> 0.05).
ALT, AST, and GGT levels were similar in the high-dose TDF
and PTX groups (p> 0.05). Each of the serum AST, ALT, and
GGT levels were statistically higher in low-dose and high-
dose TDF and PTX groups than the sham group (p< 0.001).
MDA is an index of hepatic damage associated with lipid
peroxidation and total antioxidant capacity (TAC) is used to
evaluate oxidative stress. Serum and tissue MDA and TAC
levels were significantly different in the IR group compared
with high-dose TDF and PTX groups (p< 0.05), whereas
there was no significant difference compared with low-dose
TDF group (p> 0.05). Serum and tissue MDA and TAC levels
were similar in high-dose TDF and PTX groups (p> 0.05). UA
is released in hypoxic conditions and is a potent antioxi-
dant. Serum UA levels were significantly different in the IR
group compared with low- and high-dose TDF and PTX
groups (p< 0.05), whereas no significant difference was
observed between low- and high-dose TDF and PTX groups
(p> 0.05). The biochemical characteristics of the all groups
are shown in Table 1.
Histopathological results
In the sham group, the livers showed a normal lobular ar-
chitecture with central veins and radiating hepatic cords
with a mean overall grade of 0 in each. In low- and high-
dose TDF and PTX groups, the severity of hepatic injury
showed a significant decrease when compared to IR groupTable 1 Biochemical parameters of all groups.
Sham (nZ 8) IR (nZ 8)
Serum
ALT (u/L) 660.4  220 3020.7  1249
AST (u/L) 692.8  250 3904.7  1914
GGT (u/L) 3.24  1.01 6.75  2.12
TAC (mM Trolox) 1.45  0.32 0.81  0.32
MDA (mM) 2.41  0.78 5.25  1.02
UA (mg/dL) 1.27  0.38 1.83  0.21
Tissue
TAC (nmol trolox/mg protein) 130  38.4 257.3  80.2
MDA (nmol/mg protein) 2.16  0.86 4.37  1.6
Data are presented as mean standard deviation.
ALTZ alanine aminotransferase; ASTZ aspartate aminotransferas
MDAZmalondialdehyde; PTXZ pentoxifylline; TACZ total antioxida
a p< 0.05 compared with IR group.
b p< 0.05 compared with low-dose TDF group (1-way analysis of va(p< 0.05). Hepatic injury grades of low-dose TDF and PTX
groups were similar and were not significantly different
(p> 0.05; Figure 1). High-dose TDF exerted the best his-
topathological protective effect on IR-induced liver tissue
damage (p< 0.05; Table 2). The histopathological results of
the all groups are shown in Table 2.
Immunohistochemical results
Hepatocyte apoptosis was significantly higher in the IR
group versus the high-dose TDF, PTX, and sham groups
(p< 0.05), whereas no significant difference was evident
with low-dose TDF (p> 0.05; Figure 2). The rats treated
with high-dose TDF and PTX showed a significantly lower
number of apoptotic cells. Scores for extent and intensity
of eNOS (Figure 3) and iNOS (Figure 4) were significantly
higher in IR group compared with high-dose TDF and PTX
groups (p< 0.05) but not significantly different from low-
dose TDF group (p> 0.05). eNOS and iNOS expressions
were similar in the high-dose TDF and PTX groups
(p> 0.05). The immunohistochemical results of the all
groups are shown in Table 2.
Discussion
IR is a major component of injury in vascular occlusion
during both liver transplantation and liver tumor resec-
tion. There are other conditions that decrease hepatic
blood flow and cause hepatic ischemia, such as hemor-
rhagic shock, sepsis, hepatic artery ligation, trauma, and
vascular lesions. The pathophysiology of liver IR includes a
number of mechanisms including oxidant stress formed
during IR that contribute to various degrees to organ
damage. Liver IR injury is divided into two phases. The
early phase covers the first 2 hours following reperfusion
and is dominated by Kupffer cell activation and release of
various mediators such as reactive oxygen species and
cytokines. The late phase, which commences at about 6
hours of reperfusion and continues until 48 hours post-
reperfusion, and is characterized by neutrophil infiltrationTDF (nZ 8)
2.5 mg/kg
TDF (nZ 8)
10 mg/kg
PTX (nZ 8)
40 mg/kg
2254.5  939 1018.6  137a,b 1125.5  171a,b
1823  549 1123.2  246a,b 1259.1  477a,b
6.12  0.83 3.33  1.22a,b 3.68  1.77a,b
0.89  0.34 1.68  0.39 a,b 1.87  1.75a,b
3.75  0.66 2.62  0.56a,b 2.56  1.09a,b
1.21  0.16a 1.10  0.10a 1.22  0.16a
190.1  64.1 134  25.5a,b 139.7  19.5a,b
3.82  0.64 2.33  1.02a,b 2.67  0.68a,b
e; GGTZ g-glutamyl transferase; IRZ ischemia/reperfusion;
nt capacity; TDFZ tadalafil; UAZ uric acid.
riance test).
Figure 1. (A 20) Ischemia/reperfusion group: Hepatocytes cells with severe necrosis, disintegration of hepatic cords and
hemorrhage. (B 20) Low-dose tadalafil and (C 20) pentoxifylline groups: Hepatocytes cells with moderate injury, cytoplasmic
hypereosinophilia, and loss of intercellular borders. (D 20) High-dose tadalafil group: mild injury consisting of cytoplasmic
vacuolation and focal nuclear pyknosis. (Hematoxylin and eosin).
Table 2 Hepatic injury grades and immunohistochemical expressions of apoptosis protease-activating factor 1, endothelial
and inducible nitric oxide synthases of all groups.
Sham (nZ 8) IR (nZ 8) TDF (nZ 8)
2.5 mg/kg
TDF (nZ 8)
10 mg/kg
PTX (nZ 8)
40 mg/kg
Hepatic injury grade 0.0  0.0 2.8  0.4 1.9  0.3a 0.6  0.5a,b 1.8  0.4a,c
APAF-1
Extent 0.6  0.51 2.5  0.50 1.8  0.51 1.0  0.0a,d 1.0  0.0a,d
Intensity 0.6  0.51 2.4  0.51 1.9  0.56 1.3  0.52a,d 1.3  0.48a,d
eNOS
Extent 0.4  0.51 1.4  0.51 1.3  0.48 0.8  0.42a,d 1.0  0.0a,d
Intensity 0.4  0.51 2.3  0.67 1.6  0.51 1.0  0.47a,d 1.5  0.52a,d
iNOS
Extent 0.3  0.48 1.6  0.51 1.5  0.52 0.8  0.42a,d 1.2  0.42a,d
Intensity 0.3  0.48 2.3  0.48 2.1  0.31 1.1  0.56a,d 1.2  0.42a,d
Data are presented as mean  standard deviation.
APAF-1Z apoptosis protease-activating factor 1; eNOSZ endothelial nitric oxide synthases; iNOSZ inducible nitric oxide synthases;
IRZ ischemia/reperfusion; PTXZ pentoxifylline; TDFZ tadalafil.
a p< 0.05 compared with IR group.
b p< 0.05 compared with low-dose TDF and PTX groups.
c p> 0.05 compared with low-dose TDF group.
d p< 0.05 compared with low-dose TDF group (ManneWhitney U test).
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soidal endothelial cell damage [1,2,17]. During the
ischemia as a result of glycogen consumption and lack of
oxygen supply, Kupffer cells, sinusoidal endothelial cells,
and hepatocytes suffer with lack of ATP production. The
lack of ATP leads to failure of the sodium/potassium ATP-
dependent plasma membrane pump and subsequentintracellular Naþ accumulation, edema, and swelling.
Kupffer cells and sinusoidal endothelial cells swelling
combined with an increase in the vasoconstrictors endo-
thelin and thromboxane A2 and a decrease in the vaso-
dilator nitric oxide lead to sinusoidal narrowing. The end
result is a significant reduction of microcirculatory blood
flow on reperfusion [1,2,18].
Figure 2. APAF-1 immune expression of liver cells (A 20) strong cytoplasmic staining in ischemia/reperfusion group, (B 20)
moderate cytoplasmic staining in low-dose tadalafil group, weak cytoplasmic staining in (C 20) pentoxifylline and (D 20) high-
dose tadalafil groups.
Figure 3. eNOS immune expression of liver cells (A 20) strong cytoplasmic staining in ischemia/reperfusion group, (B 20)
moderate cytoplasmic staining in low-dose tadalafil group, weak cytoplasmic staining in (C 20) pentoxifylline and (D 20) high-
dose tadalafil groups.
344 S. Bektas et al.Further, reperfusion injury is caused by the generation
of toxic oxygen free radicals with the return of blood flow
following ischemia. These free radicals can react with lipids
in the cell membranes and initiate lipid peroxidation, whichis responsible for the IR injury. During postischemic reper-
fusion, liver tissue can counteract oxidative stress by
upregulating antioxidant defenses with the help of the
antioxidant enzymes [1,2,18].
Figure 4. iNOS immune expression of liver cells (A 20) strong cytoplasmic staining in ischemia/reperfusion group, (B 20)
moderate cytoplasmic staining in low-dose tadalafil group, weak cytoplasmic staining in (C 20) pentoxifylline and (D 20) high-
dose tadalafil groups.
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cGMP. The vasodilator effect of NO is normally limited by
the PDE-mediated degradation of its second messenger
cGMP. TDF is a long-acting PDE5 inhibitor and could reduce
the degradation of cGMP in tissues. PDE5 inhibitors have
been shown to potentiate the vasodilator effect of NO,
improving vascular function in patients with erectile
dysfunction, pulmonary arterial hypertension, portal hy-
pertension, and in cirrhotic rat liver [17,19e21]. Further-
more, it has been shown that the administration of TDF may
also be useful against ischemic injury in other organs and
tissues such as neurons, skin island flaps, ovary, myocar-
dium, and kidney [10,22e25]. Baek et al. [26] showed that
10 mg/kg of TDF suppressed apoptotic neuronal cell death
and enhanced cell proliferation in the hippocampus of
maternal-separated rat pups.
PTX, a methylxanthine derivative and a nonspecific
type-4 PDE inhibitor, is clinically used in the treatment of
lower extremity claudication. PTX has been reported to
exert vasodilator effect in addition to significantly sup-
pressing inflammation and to reduce hepatocyte apoptosis
in experimental models [27]. Takhtfooladi et al. [28]
showed that 40 mg/kg of PTX reduced inflammatory cell
infiltration, hemorrhage, and edema in lung IR injury.
So¨nmez and Du¨ndar [29] reported that 50 mg/kg of PTX
ameliorated eNOS, iNOS, and neuronal NOS protein levels
and apoptotic cells in the rat kidney. The beneficial effects
of PTX are believed to occur through various mechanisms
such as inhibition of PDE, increased cAMP levels and
downregulation of tumor necrosis factor-alpha, IL-1, IL-6,
IL-12, transforming growth factor-b, interferon-g, stellate
cell activation, and procollagen-I mRNA expression [30,31].
Recent studies have implied therapeutic effects of PTX onalcoholic hepatitis, nonalcoholic fatty liver, and liver
fibrosis; however, its effect on liver IR injury remains un-
clear [30,32,33]. The results of the present study showed
that, histopathologically, high-dose TDF (10 mg/kg) and
PTX (40 mg/kg) improves hepatic architecture, hepatocyte
necrosis, hemorrhage, and neutrophil infiltration in liver IR
injury.
eNOS is constitutively expressed in liver endothelial
cells and hepatocytes. iNOS is not expressed under normal
circumstances, but it is upregulated in various cell types
including hepatocytes, neutrophils, T-lymphocytes,
endothelial, biliary, and Kupffer cells in liver IR injury.
Abu-Amara et al. [34] reported that eNOS is an essential
enzyme for the protective effects in liver IR injury.
Another study reported that iNOS had protective effects
against IR injury in heart [35]. By contrast, nitrosative
stress has also been recognized as a contributor to cellular
damage associated with IR injury. When iNOS and eNOS are
upregulated in IR injury, the excessive NO produced will
react with superoxide anion, creating peroxynitrite. Per-
oxynitrite then aggravates the injury through lipid perox-
idation, apoptosis, and necrosis by nitration of tyrosine
residues on tissue proteins [36]. In our study, immune
scores for extent and eNOS and iNOS intensities were
significantly decreased in high-dose TDF and PTX groups
compared with the IR group. This result can be explained
by reduced nitrosative stress and inhibition of hepatocytes
and endothelial cell injury subsequent to high dose TDF
and PTX administration in liver IR.
In IR injury, the mitochondrion participates in various
pathophysiological processes. There is failure of ATP pro-
duction as a consequence of disruption of oxidative
phosphorylation caused by the generation of reactive
346 S. Bektas et al.oxygen and nitrogen species. Cytosolic ionic disturbances
lead to mitochondrial ionic disturbances, and vice versa,
with consequent plasma and mitochondrial membrane
damage, including the formation of mitochondrial
permeability transition pores. Reactive oxygen and nitro-
gen species can cause oxidative damage to the enzyme
complexes of respiratory chain and release of cytochrome
C into the cytosol, triggering both apoptotic and necrotic
cell death. The protective effects of PDE5 inhibition were
recently shown to be mediated by increased intracellular
cGMP levels and the activation of mitochondrial K-ATP
channels either directly or indirectly through a variety of
signaling pathways, such as activation of protein kinase C
and protein kinase G. Mitochondrial K-ATP channel open-
ing may prevent apoptosis, presumably by inhibiting
mitochondrial Ca2þ accumulation during ischemia and by
preserving mitochondrial inner membrane potential [37].
Antiapoptotic properties of PDE5 inhibitors have been re-
ported. Sildenafil, another PDE inhibitor, inhibits
apoptosis by increasing cytochrome-c secretion and the
Bcl-2/Bax ratio through NO [38]. These mechanisms may
explain the lower APAF1 levels in high-dose TDF group and
also PTX group in this study. In addition, high-dose TDF and
PTX administration in liver may prevent apoptosis and
necrosis by reducing the formation of reactive oxygen and
nitrogen species.
TAC is used to evaluate oxidative stress. In this study,
higher serum and lower tissue levels of TAC in high-dose
TDF and PTX groups compared with the IR group could be
due to upregulation of enzymatic antioxidant defense of
liver tissue. MDA is the end product of lipid peroxidation
and is a well-known marker for free radical formation in
postischemic tissue. In our study, hepatic and serum MDA
levels were significantly decreased in high-dose TDF and
PTX groups compared to IR group. This condition indicates
that high dose TDF and PTX administration decreased free
radical formation and lipid peroxidation in liver IR.
Serum ALT, AST, and GGT levels are widely used as
markers of liver cell damage. In this study, high-dose TDF
and PTX promoted a protective effect against IR injury in
liver. UA is released in hypoxic conditions and acts as a
strong reducing agent and a potent antioxidant. We believe
that reduced UA levels by TDF and PTX administrations
could minimize liver damage.
Effective dose of PDE inhibitors are different in rats and
humans due to their different metabolic rate and half-life.
Previous studies reported that the half-life of PDE inhibitors
in rats was at least three times less than in humans
(0.4e1.3 hours in rat vs. 4 hours in humans) [39]. Therefore,
the drug doses used in rats is much higher than doses
commonly used therapeutically in humans. For example,
Kovanecz et al. [40] indicated that a 20 mg/kg daily dose of
sildenafil (PDE5 inhibitor) in rats was approximately
equivalent to a 200 mg oral daily dose in humans when
corrected for differences in total body surface area.
The cellular results of liver IR injury are necrosis and
apoptosis of hepatocytes and sinusoidal endothelial cells.
Clinically, IR injury leads to liver dysfunction, which makes
a major contribution to the morbidity and mortality of liver
surgery. Although considerable research efforts have been
made to find and eliminate underlying causes of hepatic IR
injury, many points still remain unclear.In conclusion, we have demonstrated that high-dose TDF
and PTX have beneficial histopathological and biochemical
effects that are protective against liver IR injury. This an-
imal model implies that TDF and PTX supplementation may
be helpful in preventing free oxygen radical damage, lipid
peroxidation, hepatocyte necrosis, and apoptosis in liver IR
injury and minimizing liver damage. We believe that studies
on the protective effects of TDF and PTX in liver IR damage
will lead to the proper application of type-4 and -5 PDE
inhibitors in clinical practice.References
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